Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic & Translational

Granzyme B PET Imaging Permits Stratified Ex Vivo Analysis to Better Understand Response to Immunotherapy

Benjamin Larimer, Emily Austin, Thomas LaSalle, Grant Rigney, Adriell Louis, Margaret Fisher, Sarah Nesti and Umar Mahmood
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 275;
Benjamin Larimer
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Austin
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas LaSalle
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grant Rigney
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriell Louis
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Fisher
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Nesti
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umar Mahmood
1Radiology Massachusetts General Hospital Charlestown MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

275

Objectives: While cancer immunotherapy has revolutionized the treatment of certain cancers, overall response rates remain low. In part, this is due to the complex interplay between the immune system and the tumor microenvironment. Although techniques such as flow cytometry and cytokine analysis are highly informative, their destructive nature limits the longitudinal information provided. Molecular imaging, conversely, can provide a non-invasive and quantitative examination of specific processes of interest. Previously, we developed a granzyme B PET imaging agent and demonstrated specific detection that was predictive of response to immunotherapy. Based on these findings, we utilized PET imaging in combination with flow cytometry and cytokine analysis in order to better understand the conditions and potential factors that lead to high granzyme B release.

Methods: Mice bearing CT26 or MC38 syngeneic tumors underwent granzyme B PET/CT imaging at 6 or 12 days post-initiation of anti-PD-1 plus anti-CTLA-4 combination therapy, and tumor and blood pool was quantified by drawing a three-dimensional region of interest using CT guidance. Tumor-specific accumulation was then calculated using the tumor to blood ratio (TBR). After the completion of PET imaging, tumors were excised, and a single-cell suspension generated. The supernatant of this suspension was saved for cytokine analysis using a 36-Plex Mouse Cytokine analysis kit. Cells were stained with antibodies to differentiate T cell subtypes and activation states and flow cytometry performed. As higher granzyme B PET TBR is consistent with subsequent response to immunotherapy, the TBRs were plotted against individual flow cytometry and cytokine results to explore correlations between immune cell types and cytokines and granzyme B release.

Results: PET imaging resulted in tumors with granzyme B PET TBRs ranging from 0.95 to 2.41, which was consistent with previous measurements following combination immunotherapy. When individual tumor granzyme B TBR was compared to the corresponding immune cell populations and cytokine expression, several correlations were observed. Among immune cell populations, there was a positive linear correlation between PD-1 expression and granzyme B PET signal (Figure A) but a negative correlation between granzyme B signal and PD-1-negative, granzyme B-positive CD8 T cells (Figure B). This indicates that actively tumor-killing T cells express PD-1 but become devoid of intracellular granzyme B, most likely because they have released a majority of their granules. Regulatory T cells were also positively correlated with granzyme B PET signal (Figure C), which may be a function of a negative feedback loop signaling recruiting following cytotoxic T cell activation. In addition to flow cytometry, cytokine expression was also quantified. Granzyme B PET signal was compared to concentration of 36 TH1, TH2, or TH17 cytokine (Figure D). Some expected cytokines positively correlated with granzyme B PET TBR, including IFN-gamma, TNF-alpha and GM-CSF (Figure E), but other unexpected cytokines with roles in macrophage, helper T cell and eosinophil chemotaxis were also positively correlated (Figure F).

Conclusions: Granzyme B PET imaging combined with ex vivo analysis provides a unique insight into factors that drive response to immunotherapy. In our analyses, we observed correlations between granzyme B and CD8 T cell activation/exhaustion and regulatory T cell presence. Additionally, multiple cytokines were positively correlated with granzyme B PET signal including expected cytokines like IFN-gamma and TNF-alpha, and also new cytokines involved in the trafficking of cells that are not traditionally associated with the anti-tumor immune response. These finding form the basis for new potential avenues of therapeutic intervention and suggest further investigation into the role of non-T cell immune cells in the anti-tumor immune response.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Granzyme B PET Imaging Permits Stratified Ex Vivo Analysis to Better Understand Response to Immunotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Granzyme B PET Imaging Permits Stratified Ex Vivo Analysis to Better Understand Response to Immunotherapy
Benjamin Larimer, Emily Austin, Thomas LaSalle, Grant Rigney, Adriell Louis, Margaret Fisher, Sarah Nesti, Umar Mahmood
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 275;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Granzyme B PET Imaging Permits Stratified Ex Vivo Analysis to Better Understand Response to Immunotherapy
Benjamin Larimer, Emily Austin, Thomas LaSalle, Grant Rigney, Adriell Louis, Margaret Fisher, Sarah Nesti, Umar Mahmood
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 275;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic & Translational

  • TIM3-targeted combined-modality radioimmunotherapy in hepatocellular carcinoma
  • Al18F-labeled á-MSH peptide derivative for early detection of melanoma
  • Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model
Show more Oncology: Basic & Translational

Oncology, Basic and Translational (Basic Science) II

  • 89Zr-labeled CD8 cys-diabody for imaging immunotherapy response in GBM
  • FDG-PET of mouse breast cancers on ketogenic vs. standard chow diets, with or without added rapamycin.
Show more Oncology, Basic and Translational (Basic Science) II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire